A Multicenter, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 12 Weeks Treatment With LAF237 50 mg Bid to Placebo as Add-On Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy
A Multicenter, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 12 Weeks Treatment With LAF237 50 mg Bid to Placebo as Add-On Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy
The purpose of the study is to evaluate the efficacy and safety of vildagliptin 50 mg bid as an add-on therapy to metformin in Japanese patients with T2DM. This study is being conducted to support registration of the fixed-dose combination of vildagliptin and metformin for the treatment of Type 2 diabetes mellitus (T2DM) in Japan.
Inclusion Criteria:
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Ohkawa-city, Fukuoka 831-0016, Japan
Bunkyo-ku, Tokyo 113-0031, Japan
Edogawa-ku, Tokyo 134-0084, Japan
Minato-ku, Tokyo 105-7390, Japan
Minato-ku, Tokyo 108-0075, Japan
Nerima-ku, Tokyo 177-0051, Japan
Shinagawa-ku, Tokyo 141-0032, Japan
Toshima-ku, Tokyo 171-0021, Japan